The Diuretic Effect of ENBUMYST

In a pharmacodynamic study, ENBUMYST produced similar diuretic and natriuretic effects to oral and IV bumetanide in healthy adults.

ENBUMYST Effect on Diuresis2,3

Open-label, randomized crossover study in healthy adults (N=68)

Cumulative urinary output with ENBUMYST, IV bumetanide, and oral bumetanide at 0–4 and 0–24 hours

See how ENBUMYST is administered.

Find resources to help patients access ENBUMYST.

INDICATION

ENBUMYST is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome in adults.

IMPORTANT SAFETY INFORMATION

    • ENBUMYST is contraindicated in patients with anuria, hepatic coma, or a history of hypersensitivity to bumetanide, including anaphylaxis and anaphylactoid reactions.
    • ENBUMYST is a diuretic that may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, those with inadequate electrolyte intake, and the elderly. Abnormalities may include changes in blood electrolytes, BUN, glucose, and uric acid. Monitor serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid frequently during therapy.
    • Bumetanide can cause dehydration and azotemia. Discontinue bumetanide if azotemia worsens and oliguria occurs during treatment of severe progressive renal disease.
    • Tinnitus and hearing loss (usually reversible) have been reported with loop diuretics, including bumetanide. Reports indicate that ototoxicity is associated with rapid injection, severe renal impairment, use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.
    • Due to potential altered absorption, avoid use in patients with significant nasal mucosal or structural abnormalities, such as acute episodes of rhinitis or congestion due to any cause.
    • Advise lactating women treated with ENBUMYST to monitor their breastfed infants for excessive urine output, dehydration, and lethargy.
    • Most common adverse reactions reported in ENBUMYST studies were hypovolemia and headaches. Common adverse reactions reported with the use of oral bumetanide include muscle cramps, dizziness, hypotension, nausea and encephalopathy (in patients with pre-existing liver disease).

Please see full Prescribing Information for ENBUMYST.

AUC=area under the curve; Cmax=maximum plasma concentration.

References: 1. ENBUMYST. Prescribing Information. Corstasis Therapeutics. 2. Data on File. Esperion Therapeutics, Inc. 3. Ambrosy AP, Bensimhon D, Bernstein G, et al. Randomized study comparing a novel intranasal formulation of bumetanide with oral and intravenous formulations. Circulation. 2025;151:737-740.

INDICATION

ENBUMYST is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome in adults.

IMPORTANT SAFETY INFORMATION

    • ENBUMYST is contraindicated in patients with anuria, hepatic coma, or a history of hypersensitivity to bumetanide, including anaphylaxis and anaphylactoid reactions.
    • ENBUMYST is a diuretic that may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, those with inadequate electrolyte intake, and the elderly. Abnormalities may include changes in blood electrolytes, BUN, glucose, and uric acid. Monitor serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid frequently during therapy.
    • Bumetanide can cause dehydration and azotemia. Discontinue bumetanide if azotemia worsens and oliguria occurs during treatment of severe progressive renal disease.
    • Tinnitus and hearing loss (usually reversible) have been reported with loop diuretics, including bumetanide. Reports indicate that ototoxicity is associated with rapid injection, severe renal impairment, use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.
    • Due to potential altered absorption, avoid use in patients with significant nasal mucosal or structural abnormalities, such as acute episodes of rhinitis or congestion due to any cause.
    • Advise lactating women treated with ENBUMYST to monitor their breastfed infants for excessive urine output, dehydration, and lethargy.
    • Most common adverse reactions reported in ENBUMYST studies were hypovolemia and headaches. Common adverse reactions reported with the use of oral bumetanide include muscle cramps, dizziness, hypotension, nausea and encephalopathy (in patients with pre-existing liver disease).

Please see full Prescribing Information for ENBUMYST.